Acquisition highlights of Axio Biosolutions and a snapshot of its key metrics.

A snapshot of cap table and shareholder metrics

Founded in 2008, Axio Biosolutions operates in Health Tech industry. Initially focused on creating hemostatic solutions, the company has expanded its product offerings to serve both trauma and surgical care markets. Axio Biosolutions launched MaxioCel, an advanced chitosan-based wound care product, enhancing its portfolio for chronic wound management. Further extending its reach, the company expanded its operations to South America and the Middle East. Competing with companies such as Consure Medical and Zoplar.

Leo Mavely

Funding highlights of Axio Biosolutions and a snapshot of its key metrics.

TrueScale Capital

Omidyar Network India

GVFL

RNT Capital

Chiratae Ventures

Omidyar Network

Accel

Department of Science and Technology

UC-RNT Fund

Investment highlights of Axio Biosolutions and a snapshot of its key metrics.

Read the latest news on Axio Biosolutions covering funding updates, financials, leadership changes and key announcements on Inc42.

Axio Biosolutions Latest News 2026 – Funding, Financials & Updates

Axio Biosolutions

A snapshot of highlights, scale, and metrics

An overview of key people in Axio Biosolutions.

A Health Tech Funded Company Based Out Of Ahmedabad

Axio Biosolutions - Latest News, Analysis, Funding, Financials & More

Recent Stories on Axio Biosolutions

Medtech Startup Axio Biosolutions Raises $6 Mn From TrueScale Capital, Existing Investors

How Indigenous Trauma Care Startup Axio Biosolutions Aims to Reduce Deaths Due to Uncontrollable Bleeding On Indian Borders And Roads Alike